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By 2012, the estimated number of children (0 - 14 years of age) 
receiving antiretroviral therapy (ART) in South Africa (SA) was 
140  541, representing an estimated 63% of those requiring treat-
ment. [1,2] As increasing numbers of children are started on first- and 
second-line ART, the demand for third-line regimens in children and 
adolescents with treatment failure is likely to increase. It is estimated 
that currently <1% of people on ART globally are receiving third-line 
regimens, and it is unknown what proportion of these are children.[3]
An unpublished systematic review presented in 2015 assessing 
second- and third-line ART options for children and adolescents 
concluded that there is insufficient evidence to directly evaluate 
alternative second- and third-line ART options for children, and 
that current recommendations are still based on inference from 
adult trials.[4] The World Health Organization (WHO) recommends 
that national programmes should develop policies for third-line 
ART that should incorporate integrase strand transfer inhibitors 
(INSTIs), second-generation protease inhibitors (PIs) and second-
generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
with minimal risk of cross-resistance to previously used regimens. 
Recommended third-line ART regimens in the WHO 2016 
guidelines[5] are: (i) darunavir/ritonavir (DRV/r) plus dolutegravir 
(DTG) (or raltegravir (RAL)) with or without one to two nucleoside 
reverse transcriptase inhibitors (NRTIs); (ii) DRV/r plus two NRTIs 
with or without one NNRTI; or (iii) RAL (or DTG) plus two NRTIs, 
depending on the preceding first- and second-line ART regimens.
Although safety and efficacy of DRV/r, etravirine (ETR) and RAL 
have been reported in specific age groups of ART-naive and ART-
experienced children and adolescents, there is a paucity of data on 
treatment-experienced children from resource-constrained settings 
receiving these drugs as part of routine care.[6-14] In addition, DRV/r 
is not recommended in children <3 years of age owing to toxicity 
concerns in animal studies, and ETR, a second-generation NNRTI, is 
not recommended in children <6 years of age owing to lack of safety 
and efficacy data. Until very recently, DTG was only recommended 
by the US Food and Drug Administration (FDA) for adolescents 
>12 years of age and >40 kg body weight.[15] The FDA has recently 
approved DTG from 6 to <12 years and ≥30 kg in a dose of 35 mg 
once daily, but suitable formulations that allow for administration of 
this dose are not yet registered in SA.[16] In SA, DTG has only been 
approved from 18 years of age.
Objective
To describe the characteristics and early outcomes of treatment-
experienced children and adolescents (<20 years of age) in the 
Western Cape Province of SA who initiated an ART regimen that 
included one or more of DRV/r, RAL and ETR.
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Background. There is an increasing need for third-line treatment regimens in HIV-infected children with antiretroviral treatment (ART) 
failure. Data are limited on darunavir/ritonavir (DRV/r)-, raltegravir (RAL)- and etravirine (ETR)-containing regimens in treatment-
experienced children from resource-constrained settings receiving these drugs as part of routine care.
Objective. To describe the characteristics and early outcomes of treatment-experienced children (<20 years of age) in the Western Cape 
Province of South Africa treated with DRV/r-, RAL- or ETR-containing regimens.
Methods. This was a retrospective review of treatment-experienced children receiving a DRV/r-, RAL- or ETR-containing regimen as 
recommended by a paediatric expert review committee, based on HIV drug resistance testing.
Results. Thirty-five children of median age 8.8 years (interquartile range (IQR) 5.5 - 11) who had received ART for a median of 6.9 years 
(IQR 5 - 9.9) and started a DRV/r-, RAL- or ETR-containing regimen were included. Before starting such a regimen, the median CD4+ 
lymphocyte count and HIV-1 RNA level were 405.5 cells/µL (IQR 251.5 - 541) and 28 314 copies/mL (IQR 5 595.5 – 120 186.5) (log 4.5 
(IQR 3.7 - 5)), respectively, in 24 subjects with available results. After a median of 2 years (IQR 1.3 - 4) on treatment, 29/30 (96.7%) and 
23/30 (76.7%) subjects with available results had HIV-1 RNA levels of <400 and <50 copies/mL, respectively.
Conclusions. This study found DRV/r-, RAL- and ETR-containing regimens to be effective in a group of treatment-experienced children 
and adolescents with multidrug-resistant HIV. Although the treatment regimens in this study were individualised based on HIV genotyping 
results, further research evaluating the safety and efficacy of standardised third-line treatment regimens in children of all ages is needed.
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Methods
The Western Cape paediatric ART expert review committee (ERC) 
was constituted in October 2013. Clinicians managing children and 
adolescents with antiretroviral (ARV) drug resistance on genotype 
resistance testing (GRT) submitted a standardised application form 
requesting guidance on further treatment to the ERC. The main 
eligibility criterion for treatment with DRV/r, RAL or ETR was the 
presence of PI resistance on GRT, defined as a lopinavir/ritonavir 
(LPV/r) or atazanavir/ritonavir (ATV/r) mutation score (MS) of ≥15 
using the Stanford University HIV genotypic resistance interpretation 
algorithm.[17]
Individualised treatment recommendations for patients were made 
on a consensus basis by the ERC taking into account age, weight, 
previous ARV exposure, concomitant medication, availability of 
paediatric formulations of newer-generation ARV drugs, and an 
assessment of adherence to medication provided by the applicant. 
In April 2015, a consensus treatment algorithm based on local 
and international expert opinion, available data and international 
guidelines was adopted by the ERC in an attempt to standardise 
recommendations based on patterns of ARV drug resistance and 
MSs. According to this algorithm, all patients with an LPV/r or 
ATV/r MS of ≥15 would receive DRV/r plus either lamivudine (3TC) 
or emtricitabine (FTC), and either zidovudine (AZT) or abacavir 
(ABC) depending on which had the lowest MS. Tenofovir (TDF) 
was considered in patients aged >12 years and weighing >40 kg with 
normal renal function. Indications for the inclusion of RAL included 
low-level or higher resistance to DRV/r (MS ≥15) or no active NRTIs 
being available (ABC, AZT and TDF MS ≥30). ETR was considered 
for inclusion in the regimen in addition to RAL if the genotype 
indicated low-level or higher resistance to DRV/r, no active NRTIs 
were available and the ETR MS was <30, particularly if there was no 
known previous exposure to NNRTIs.
Children and adolescents who were already receiving ARV 
regimens containing DRV/r, RAL or ETR prior to the establishment 
of the provincial ERC were also reviewed by the ERC and included 
in the study database. These patients were identified by the Western 
Cape HIV/AIDS, sexually transmitted infections and tuberculosis 
(HAST) pharmaceutical policy specialist because they were receiving 
drugs that were not included on the provincial pharmaceutical code 
list at the time. The clinicians managing these patients were requested 
by the HAST pharmaceutical policy specialist to submit application 
forms and HIV resistance tests to the Western Cape ERC motivating 
for the continued use of these ARV regimens.
Children and adolescents were managed at a wide spectrum of 
healthcare facilities ranging from primary care clinics to district, 
regional and tertiary hospitals by the attending clinician who 
submitted the application to the ERC. There was no standardised 
adherence support or follow-up by specialists other than what was 
routinely provided at the healthcare facility where the patient was 
managed. Recommended monitoring was according to provincial 
guidelines: HIV-1 RNA after 6 and 12 months on treatment and then 
annually if suppressed or 3 - 6-monthly if not suppressed, CD4+ 
lymphocyte count annually until >200 cells/µL, and monitoring of 
serum creatinine and full blood count recommended in patients on 
TDF and AZT, respectively.[18]
The data sources for this study comprised the following: 
application forms and HIV resistance test results, including Stanford 
University HIV genotypic resistance interpretation results performed 
at the time of the application, submitted by referring clinicians to 
the Western Cape ERC; ARV treatment recommendations by the 
ERC; and available laboratory test results following initiation of the 
recommended ARV regimens. The lead author (JN) is a member of 
the ERC and accessed the data from the electronic submissions to 
the ERC that are emailed to the ERC members by the Western Cape 
HAST pharmaceutical policy specialist.
The following data on treatment-experienced children and 
adolescents (<20 years of age at the time of application) who 
initiated a DRV/r-, RAL- or ETR-containing ART regimen prior to 
October 2016 were entered by one of the authors (VP) into a study 
database: demographic and HIV disease characteristics, previous 
ARV exposure, spectrum of HIV drug resistance mutations, ARV 
treatment regimens approved by the ERC, and early treatment 
outcomes. For the purposes of this study, the following definitions 
were used: a first-line treatment regimen refers to the first ART 
regimen (comprising three or more ARV drugs) that a child or 
adolescent was initiated on; a second-line treatment regimen refers 
to a single-class switch from NNRTI to PI or vice versa, regardless of 
NRTI changes; and a third-line treatment regimen refers to an ART 
regimen that includes one or more of the ARVs DRV/r, RAL and 
ETR, even though the child or adolescent may have received less than 
two, or three or more, previous ART regimens.
Data were coded using unique study number identifiers and stored 
in a secure password-protected study database accessible only to the 
study investigators. Data quality was ensured by the lead author (JN) 
manually checking data entry accuracy by comparing application 
forms and HIV resistance test results with the database.
A descriptive analysis was performed of the following patient 
characteristics at the time of application to the ERC: age, gender, 
level of healthcare facility at which the patient was being managed, 
CD4+ lymphocyte counts and/or percentages, HIV-1 RNA levels, 
and current and previous ARV regimens. In addition, ARV drug 
resistance mutations and MS (according to the Stanford University 
HIV genotypic resistance interpretation algorithm performed at the 
time that the genotypic resistance test/s were done or, if not done then, 
at the time of application to the ERC[17]) were analysed along with the 
ARV treatment recommendations made by the ERC. Mutations were 
not re-entered into a current version of the Stanford algorithm, and 
cumulative or composite genotypes were not performed.
Treatment outcome measures analysed were HIV-1 RNA levels and 
CD4+ lymphocyte counts/percentages measured within 12 months 
of commencing a third-line ART regimen and at the time of analysis. 
CD4+ lymphocyte counts and percentages as well as HIV-1 RNA 
levels were measured by the National Health Laboratory Service.
Standard measures of frequency were used to express data. Median 
and interquartile range (IQR) values were used to describe numerical 
variables, while frequencies and percentages were used to describe 
categorical variables. Data were analysed using the Stata release 12.0 
statistical software package (StataCorp, USA).
The study was approved by the Departmental Research Committee, 
Department of Paediatrics and Child Health, University of Cape 
Town, and the Human Research Ethics Committee, Faculty of Health 
Sciences, University of Cape Town (ref. no. 259/2015).
Results
Between October 2013 and October 2016, 45 applications were 
reviewed. At the time of application, 13 children (28.9%) were 
already receiving a DRV/r-containing ART regimen; 11 of them 
were also receiving RAL. No child was receiving ETR. Fourteen 
children (31.1%) were receiving holding regimens (nine were on 3TC 
monotherapy and five on triple-NRTI regimens).
A further 22 children started a DRV/r-, RAL- or ETR-containing 
ART regimen between October 2013 and October 2016. The total 
107       February 2018, Vol. 108, No. 2
RESEARCH
study population comprised 35 children. The number of children 
starting a DRV/r-, RAL- or ETR-containing ART regimen each year 
from 2010 to 2016 was 1, 4, 3, 2, 4, 13 and 8. A temporary holding 
regimen consisting of 3TC monotherapy or a triple-NRTI regimen 
was recommended by the ERC for the 10 children excluded from 
this analysis.
The characteristics of the 35 study participants receiving a DRV/r-, 
RAL- or ETR-containing ART regimen are shown in Table 1. Twelve 
of the 35 participants (34.3%) had received only one previous ART 
regimen before starting on the DRV/r-, RAL- or ETR-containing 
regimen (all RTV- or LPV/r-based first-line ART, including single-
drug substitutions from RTV to LPV/r, a single NRTI switch, or 
temporary 3TC monotherapy).
The proportion of participants with resistance to selected 
ARV drugs prior to starting treatment on a DRV/r-, RAL- or 
ETR-containing ART regimen is summarised in Fig. 1. Thirty-
two (91.4%) and 31 (88.6%) participants had an MS of ≥15 to 
LPV/r and ATV/r, respectively, using the Stanford University HIV 
genotypic interpretation algorithm. Eighteen participants (51.4%) 
had mutations conferring low- (n=17, 48.6%) or intermediate-level 
(n=1, 2.9%) resistance to DRV/r. None had high-level resistance. The 
proportion of study subjects with each PI mutation, including DRV 
resistance-associated mutations, detected prior to starting treatment 
on a DRV/r-, RAL- or ETR-containing ART regimen is shown 
in Fig. 2. Sixteen participants (45.7%) had mutations conferring 
low- (n=6, 17.1%), intermediate- (n=8, 22.9%) or high-level (n=2, 
5.7%) resistance to ETR. Resistance testing did not include INSTI 
mutations, as none of the participants had been exposed to this class 
of drugs at the time of genotyping.
The DRV/r-, RAL- or ETR-containing ART regimens, median 
duration on treatment at the time of analysis and CD4+ and HIV-1 
RNA outcomes are summarised in Table 2. Since not all participants 
had blood tests performed at 6 and/or 12 months on treatment, the 
outcomes are expressed as median (IQR) values within 12 months 
of starting treatment and at the time of the analysis. We were able 
to access significantly fewer CD4+ lymphocyte count results than 
HIV-1 RNA results, both within 12 months of starting treatment 
(n=23) and at the time of analysis (n=21). Among 32 (91.4%) and 
30 (85.7%) participants with HIV-1 RNA results available within 
12 months of starting treatment and at a median of 2 years (IQR 1.3 - 
4), respectively, 96.9% had HIV-1 RNA levels <400 copies/mL at both 
time points. Of participants with available results, 75.0% and 76.7% 
had HIV-1 RNA levels <50 copies/mL within 12 months of treatment 
and at a median of 2 years (IQR 1.3 - 4), respectively, while only one 
had HIV-1 RNA levels of ≥400 copies/mL at the two time points. The 
ERC received no reports of drug-related adverse events or deaths.
Discussion
This is the largest description of children and young adolescents 
treated with third-line ARVs in a public sector programme in 
SA. Based on the recommendations of the ERC, 34/35 children 
(97.1%) received DRV/r, 25/34 (73.5%) received RAL in addition to 
DRV/r, and only 3/34 (8.8%) receiving DRV/r received both RAL 
and ETR in addition (Table 2). Despite the study subjects having 
Table 1. Characteristics of study participants (N=35) receiving a DRV/r-, RAL- or ETR-containing ART regimen in the Western Cape 
Province, SA
Characteristic
Age (yr), median (IQR) 8.8 (5.5 - 11)
Female, n (%) 15 (42.9)
Year of 1st-line ART initiation, n (%)
Before 2004 2 (5.7)
2004 - 2007 23 (65.7)
2008 - 2011 7 (20.0)
2012 - 2014 3 (8.6)
Years on ARVs prior to starting a DRV/r-, RAL- or ETR-containing ART regimen, median (IQR) 6.9 (5 - 9.9)
Number of ARVs exposed to prior to starting a DRV/r-, RAL- or ETR-containing ART regimen, 
median (IQR)
NRTIs 4 (2 - 4)
NNRTIs 1 (0 - 1)
PIs 1 (1 - 2)
Previous exposure to unboosted PI (full-dose ritonavir)-containing 1st-line ART, n (%) 13 (37.1)
ART treatment site at time of referral to ERC, n (%)
Primary care clinic 13 (37.1)
District hospital 3 (8.6)
Regional hospital/tertiary referral hospital 19 (54.3)
Provincial distribution at time of referral to ERC, n (%)
Within Cape Town metropolitan area 28 (80.0)
Outside Cape Town metropolitan area 7 (20.0)
Prior to starting a DRV/r-, RAL- or ETR-containing ART regimen, median (IQR)
CD4+ lymphocyte count (cells/μL) 405.5 (251.5 - 541) (n=24)
CD4+ lymphocyte percentage 14.9 (8.3 - 20.3) (n=13)
HIV-1 RNA, copies/mL 28 314 (5 595.5 - 120 186.5) (n=24)
HIV-1 RNA, log 4.5 (3.7 - 5.0) (n=24)
DRV/r = darunavir/ritonavir; RAL = raltegravir; ETR = etravirine; ART = antiretroviral therapy; SA = South Africa; IQR = interquartile range; ARVs = antiretrovirals; NRTI = nucleoside reverse 
transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; ERC = expert review committee.
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multidrug-resistant HIV prior to starting treatment with these 
regimens, including low-level DRV/r resistance in almost 50%, we 
found impressive early treatment outcomes. Both within 12 months 
of treatment and after a median period of 2 years (IQR 1.3 - 4) on 
treatment, >96.5% of the participants with available results (86 - 91% 
at the two time points, respectively) had achieved HIV-1 RNA levels 
<400 copies/mL. Although significantly fewer CD4+ lymphocyte 
counts and percentage results were available both before and after 
starting a third-line regimen, the median CD4+ lymphocyte count of 
717 cells/µL (IQR 513 - 980) after a median of 2 years on treatment 
indicates good immunological reconstitution in participants with 
available results.
Just over half of the children received treatment with third-line 
ARV regimens at regional or tertiary hospitals, the remainder 
attending district-level hospitals or primary care clinics (Table 1). 
Decentralisation of care from large urban hospital settings to smaller 
rural hospitals and clinics is critically important in improving access 
to treatment for patients who may not be able to reach centralised 
healthcare facilities owing to financial and transport constraints. This 
is an important strength of this study.
It is significant that approximately a third of the participants (34.3%) 
had received only one previous ART regimen (RTV- or LPV/r-based 
first-line ART, including single-drug substitutions from RTV to 
LPV/r, a single NRTI switch, or temporary 3TC monotherapy) before 
starting on the DRV/r-, RAL- or ETR-containing regimen, which was 
effectively a second-line ART regimen for these participants. In SA 
guidelines prior to 2010, the recommended second-line ART regimen 
for children or adolescents failing PI-based first-line ART was an 
NNRTI plus two NRTIs.[19] In the current SA guidelines (2014),[20] there 
is no standardised second-line treatment regimen for children failing 
first-line PI-based ART and no standardised third-line ART regimens. 
It is recommended that these children should be referred to an ERC so 
that treatment with third-line agents (including DRV/r, RAL and ETR) 
can be considered following interpretation of the GRT and taking into 
account prior ARV exposure.[20] Although current WHO guidelines 
recommend a second-line regimen comprising two NRTIs plus either 
EFV or RAL for children failing first-line LPV/r-based ART, there is a 
lack of data to support these recommendations.[5]
The WHO guidelines do not define specific criteria for the 
inclusion of INSTIs, NNRTIs or NRTIs into third-line ART 
regimens. [5] In a French cohort of 12 highly ARV-experienced 
adolescents all treated with a combination of DRV/r, RAL and ETR 
with additional ARVs in some patients, 11/12 (91.7%) achieved 
HIV-1 RNA levels of <400 copies/mL after a median of 12 months, 
with 6 (50.0%) achieving <50 copies/mL. In addition, medication 
was generally well tolerated with no grade 3 or 4 adverse events 
reported and no treatment discontinuations.[6] Other than phase 2 
trials under controlled conditions, two other retrospective studies 
involving treatment-experienced adolescents in Spain receiving RAL- 
or ETR-based regimens in combination with other ARVs have found 
comparable safety and efficacy outcomes.[7,8,10-12]
Although GRT is a prerequisite for accessing these medications 
in the SA public sector, specific indications for resistance testing are 
not included in the 2014 national guidelines, and access to GRT has 
not been uniform in the SA public sector. Before 2015, GRT was 
generally only available to patients with private medical insurance 
or through research studies or donor-funded access programmes in 
the public sector. Since April 2015, access to GRT in the Western 
Cape public health sector has required written motivation by 
the clinician manging the patient and approval by the provincial 
Department of Health. Patients on a PI-based ART regimen with 
HIV-1 RNA non-suppression (defined as at least three HIV-1 RNA 
measurements of ≥1 000 copies/mL (≥ log 4.5) at least 8 - 12 weeks apart), 
with the most recent HIV-1 RNA level result within 3 - 6 months of 
the application, are eligible for GRT. In addition, children and early 
adolescents (<15 years of age) must have been receiving a PI-based 
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Fig. 1. Proportion of study subjects with resistance to selected ARV drugs 
prior to starting treatment on a DRV/r -, RAL- or ETR-containing antiretro-
viral therapy regimen. Drug resistance interpretation by mutation score 
category is according to the Stanford University HIV genotypic resistance 
interpretation algorithm performed at the time that the genotypic resistance 
test/s were done or, if not done then, at the time of application to the Expert 
Review Committee. (ARV = antiretroviral; DRV/r = darunavir/ritonavir; 
RAL = raltegravir; ETR = etravirine; ATV/r = atazanavir/ritonavir; 
DRV/r = darunavir/ritonavir; LPV/r = lopinavir/ritonavir; ABC = abacavir; 
AZT = zidovudine; 3TC/FTC = lamivudine/emtricitabine; TDF = tenofovir; 
NVP = nevirapine; EFV = efavirenz; RPV = rilpivirine; PIs  = protease 
inhibitors; NRTIs = nucleoside reverse transcriptase inhibitors; NNRTIs = 
non-nucleoside reverse transcriptase inhibitors; MS = mutation score 
according to the Stanford University HIV genotypic resistance interpretation 
algorithm.[17])
 
PI mutations
25
.7
%
L1
0F
 L
10
I
 L
10
V
V1
1I
*
K2
0T
L2
4I
D
30
N
L3
3F
*
K4
3T
M
46
I
I5
0L
 I5
0V
*
I5
4V
O
58
E
 T
74
P*
T7
4S
 L
76
V*
V8
2A
V8
2C
 V
82
L
V8
2M
 V
82
S
 I8
4V
*
 L
90
M
45
.7
%
8.
6%
8.
6%
2.
9%
2.
9%
2.
9%
2.
9%
14
.3
%
2.
9%
 5
7.
1%
 2
.9
% 5.
7%
68
.6
%
 
14
.3
%
2.
9% 5.
7%
34
.3
%
62
.9
%
5.
7%
 2
.9
%
5.
7%
 
 2
.9
%
11
.4
%
Pa
rt
ic
ip
an
ts
 w
ith
 e
ac
h 
PI
 m
ut
at
io
n 
de
te
ct
ed
, n
 a
nd
 %
35
30
25
20
25
10
5
0
Fig. 2. Proportion of study subjects with each PI mutation detected prior 
to starting treatment on a DRV/r-, RAL- or ETR-containing ARV therapy 
regimen. (PI = protease inhibitor; DRV/r = darunavir/ritonavir; RAL  = 
raltegravir; ETR = etravirine; ARV = antiretroviral; *DRV resistance-
associated mutations.)
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ART regimen for at least 1 year, and adults and late adolescents 
(≥15 years of age) must have been receiving a PI-based ART 
regimen for at least 2 years.[18]
An important factor that may have contributed to the development 
of significant PI resistance in the study subjects is failure to have 
achieved viral suppression while on treatment with an unboosted 
PI-based ART regimen. Such regimens were previously used to 
treat children <6 months of age and children requiring concomitant 
rifampicin (RIF)-based antituberculosis treatment. Unboosted PIs 
are known to be associated with the development of major PI 
resistance mutations in children with virological failure.[21-23] In our 
study, 13/35 subjects (37.1%) had received previous treatment with 
a RTV-based regimen. Pharmacokinetic interactions between RIF 
and LPV/r resulting in subtherapeutic plasma LPV levels may also 
predispose to the development of PI resistance.[24-26] Adjustment of 
first- or second-line ART regimens to avoid this problem may not 
have been done in all cases. However, detailed information on TB 
co-infection and treatment was not included in this study.
The presence of high rates of NNRTI resistance mutations 
conferring resistance to ETR in nearly 50% of subjects is likely to 
reflect virological failure on first- or second-line NNRTI-based ART 
regimens. However, genotyping is not routinely performed at the 
time of first-line ART failure, and this may be an underestimation 
of the true prevalence of NNRTI mutations conferring resistance to 
ETR. Once the patient is no longer receiving NNRTI-based ART, 
some mutations may remain present at low levels not detected by 
routine genotyping done at the time of second-line ART failure. 
Previous studies have described high-level ETR resistance in almost 
50% of children failing first-line NNRTI-based ART.[27,28] These 
findings call into question the role of ETR in second- and third-line 
ART regimens in NNRTI-exposed individuals.
Although adult and some paediatric formulations of DRV, RAL 
and ETR are registered in SA, these are often inappropriate for 
young children, in whom doses must be adjusted for age and weight 
changes. Young children who are unable to swallow tablets require 
dispersible or chewable tablets or oral suspensions. Although RAL 
chewable tablets are now available in SA, oral suspensions of DRV, 
RAL and ETR are not registered here and are only available on 
compassionate access programmes from manufacturers and with 
approval from the Medicines Control Council of SA. In addition, 
DRV/r is not currently available as a co-formulated medication, 
so RTV needs to be provided separately, adding to the pill burden 
of third-line regimens. Access to and palatability of RTV oral 
suspension remains a significant barrier to third-line ART for 
younger children.
Study limitations
This study has a number of limitations related to its retrospective 
nature and the fact that participants were managed at multiple 
healthcare facilities across the province without direct oversight 
by members of the ERC. We were unable to obtain complete data 
on HIV-1 RNA levels and CD4+ lymphocyte counts on all study 
participants both before and after they started their DRV/r-, RAL- or 
ETR-containing ART regimens. Some participants had started these 
regimens months or years prior to being reviewed by the ERC, and 
the data were not always supplied by the referring clinicians or could 
not be traced from an earlier electronic laboratory reporting system. 
Since this was not a prospective study, monitoring of HIV-1 RNA 
levels, CD4+ lymphocyte counts and adverse events may not always 
have been performed according to standard provincial monitoring 
guidelines. Information regarding maternal ART and exposure 
of participants to prevention of mother-to-child transmission of 
HIV would have contributed to an understanding of participants 
with NNRTI mutations in whom there was no history of previous 
NNRTI-based ART regimens. The children and adolescents reviewed 
by the ERC and started on third-line ART regimens may not be 
representative of other children who are failing first- or second-
line ART in other regions and who may not have undergone 
genotyping. Documentation of prior treatment with unboosted 
PI-based ART and prior concomitant PI-based ART treatment 
and antituberculosis treatment was common, but data were not 
available for all participants. This study involved a small number 
of participants receiving individualised ARV combinations based 
on current and historical genotype results and prior ARV history 
interpreted by an ERC and is not able to compare the relative 
effectiveness of the different treatment regimens used.
Table 2. DRV/r-, RAL- or ETR-containing ART regimens started in study participants (N=35), with overall immunological and 
virological outcomes on treatment
ART regimen Children, n (%)
DRV/r + 2 NRTIs 9 (25.7)
DRV/r + RAL + 1 NRTI 8 (22.8)
DRV/r + RAL + 2 NRTIs 14 (40.0)
DRV/r + RAL + ETR + 1 NRTI 3 (8.6)
ETR + LPV/r + 1 NRTI 1 (2.9)
Treatment duration Years, median (IQR)
Duration of DRV/r-, RAL- or ETR-containing ART at time of analysis 2 (1.3 - 4)
Outcomes Within 12 months At time of analysis
CD4+ count (cells/μL), median (IQR) 649 (506 - 900)
(n=23)
717 (513 - 980)
(n=21)
CD4+ lymphocyte percentage, median (IQR) 27.1 (20.8 - 36.4)
(n=23)
27.2 (20.8 - 35.6)
(n=21)
HIV-1 RNA (copies/mL), n (%) (n=32) (n=30)
<50 24 (75.0) 23 (76.7)
<400 31 (96.9) 29 (96.7)
≥400 1 (3.1) 1 (3.3)
DRV/r = darunavir/ritonavir; RAL = raltegravir; ETR = etravirine; ART = antiretroviral therapy; NRTI = nucleoside reverse transcriptase inhibitor; IQR = interquartile range.
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Conclusions
This study found DRV/r-, RAL- or ETR- containing ART regimens to 
be effective in a group of ART-experienced children and adolescents 
with multidrug-resistant HIV. Although the ART regimens in this 
study were individualised based on genotyping results, further 
research evaluating the safety and efficacy of standardised third-
line treatment regimens in children of all ages and adolescents is 
needed in order to improve access in settings where genotyping is 
not routinely available.
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